Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more
Collegium Pharmaceutical Inc (COLL) - Net Assets
Latest net assets as of September 2025: $274.81 Million USD
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has net assets worth $274.81 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.61 Billion) and total liabilities ($1.33 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $274.81 Million |
| % of Total Assets | 17.1% |
| Annual Growth Rate | 40.15% |
| 5-Year Change | 23.01% |
| 10-Year Change | 169.0% |
| Growth Volatility | 107.92 |
Collegium Pharmaceutical Inc - Net Assets Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual net assets of Collegium Pharmaceutical Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $228.84 Million | +17.10% |
| 2023-12-31 | $195.43 Million | +0.30% |
| 2022-12-31 | $194.84 Million | -3.98% |
| 2021-12-31 | $202.93 Million | +9.08% |
| 2020-12-31 | $186.03 Million | +112.77% |
| 2019-12-31 | $87.43 Million | -4.53% |
| 2018-12-31 | $91.58 Million | -12.01% |
| 2017-12-31 | $104.08 Million | -22.85% |
| 2016-12-31 | $134.91 Million | +58.58% |
| 2015-12-31 | $85.07 Million | +794.98% |
| 2014-12-31 | $-12.24 Million | -319.29% |
| 2013-12-31 | $5.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Collegium Pharmaceutical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8346300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $40.00K | 0.02% |
| Other Comprehensive Income | $55.00K | 0.02% |
| Other Components | $392.75 Million | 171.62% |
| Total Equity | $228.84 Million | 100.00% |
Collegium Pharmaceutical Inc Competitors by Market Cap
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brigade Enterprises Limited
NSE:BRIGADE
|
$961.22 Million |
|
Nordic American Tankers Limited
NYSE:NAT
|
$961.35 Million |
|
Vipshop Holdings Limited
NYSE:VIPS
|
$961.46 Million |
|
Netmarble Games Corp
KO:251270
|
$961.51 Million |
|
PROG HOLDINGS A DL-50
F:AZD
|
$960.90 Million |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
$960.51 Million |
|
Jiangsu Leili Motor Corp Ltd
SHE:300660
|
$960.33 Million |
|
U.S. Physical Therapy Inc
F:UPH
|
$959.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Collegium Pharmaceutical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 195,431,000 to 228,842,000, a change of 33,411,000 (17.1%).
- Net income of 69,190,000 contributed positively to equity growth.
- Share repurchases of 60,025,000 reduced equity.
- Other comprehensive income increased equity by 41,000.
- Other factors increased equity by 24,205,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $69.19 Million | +30.23% |
| Share Repurchases | $60.02 Million | -26.23% |
| Other Comprehensive Income | $41.00K | +0.02% |
| Other Changes | $24.20 Million | +10.58% |
| Total Change | $- | 17.10% |
Book Value vs Market Value Analysis
This analysis compares Collegium Pharmaceutical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 47.81x to 6.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.75 | $35.72 | x |
| 2014-12-31 | $-1.64 | $35.72 | x |
| 2015-12-31 | $6.28 | $35.72 | x |
| 2016-12-31 | $5.56 | $35.72 | x |
| 2017-12-31 | $3.44 | $35.72 | x |
| 2018-12-31 | $2.78 | $35.72 | x |
| 2019-12-31 | $2.61 | $35.72 | x |
| 2020-12-31 | $5.29 | $35.72 | x |
| 2021-12-31 | $4.94 | $35.72 | x |
| 2022-12-31 | $5.76 | $35.72 | x |
| 2023-12-31 | $4.68 | $35.72 | x |
| 2024-12-31 | $5.66 | $35.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Collegium Pharmaceutical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 30.23%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.96%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 7.27x
- Recent ROE (30.23%) is above the historical average (-36.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -290.16% | 0.00% | 0.00x | 1.62x | $-16.76 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.69 Million |
| 2015 | -32.04% | 0.00% | 0.00x | 1.15x | $-35.76 Million |
| 2016 | -69.81% | -5504.15% | 0.01x | 1.20x | $-107.67 Million |
| 2017 | -71.93% | -262.91% | 0.21x | 1.30x | $-85.27 Million |
| 2018 | -42.72% | -13.95% | 0.96x | 3.18x | $-48.29 Million |
| 2019 | -25.99% | -7.66% | 0.97x | 3.50x | $-31.47 Million |
| 2020 | 14.38% | 8.63% | 0.48x | 3.46x | $8.15 Million |
| 2021 | 35.24% | 25.83% | 0.40x | 3.41x | $51.22 Million |
| 2022 | -12.83% | -5.39% | 0.40x | 6.03x | $-44.49 Million |
| 2023 | 24.64% | 8.50% | 0.50x | 5.85x | $28.61 Million |
| 2024 | 30.23% | 10.96% | 0.38x | 7.27x | $46.31 Million |
Industry Comparison
This section compares Collegium Pharmaceutical Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc (COLL) | $274.81 Million | -290.16% | 4.85x | $961.17 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |